U.S. lawmakers are pressing Health Secretary Robert F. Kennedy Jr. for answers over a potential conflict of interest involving litigation against Merck and its Gardasil HPV vaccine. Four Democratic senators, including Elizabeth Warren, have asked Kennedy to clarify whether he or members of his family could financially benefit from a $50 million settlement reached earlier this year in lawsuits involving the vaccine. The senators are also questioning whether Kennedy should recuse himself from federal decisions involving Gardasil while overseeing agencies responsible for vaccine policy and regulation.
The issue stems from Kennedy’s work as an attorney before joining the Trump administration. He had been involved in litigation against Merck on behalf of people who alleged injuries connected to Gardasil. After becoming health secretary, Kennedy said that his financial interest in vaccine related litigation would be transferred to one of his sons. One of his sons, Conor Kennedy, works at the law firm Wisner Baum, which has represented plaintiffs in Gardasil cases. The senators are now seeking details about whether any settlement related fees were transferred and, if so, how much was involved.
Kennedy Faces Questions Over Gardasil Conflict
The controversy is particularly significant because Kennedy now has responsibility for federal agencies involved in vaccine regulation and public health policy. According to the senators’ letter, Kennedy has not committed to recusing himself from decisions concerning Gardasil or broader policies affecting vaccine litigation. They argue that even the appearance of a financial connection could raise questions about the independence of government decisions. The lawmakers have requested a response by August 11, while the Department of Health and Human Services has not yet provided a public response to the inquiry.
Wisner Baum has disputed the suggestion that Kennedy or his son will profit from the settlement. The firm’s managing partner, Brent Wisner, told Reuters that neither Kennedy nor his son will receive fees from the Gardasil settlement. Merck has also consistently maintained that Gardasil is safe and effective. The dispute therefore centers not only on the vaccine litigation itself, but also on whether Kennedy’s previous legal work and family connections could create a conflict while he is responsible for shaping national health policy.
The questions come amid wider debate over the future of HPV vaccination in the United States. The CDC has historically recommended routine HPV vaccination beginning at ages 11 or 12, with vaccination possible from age nine, because HPV infections can lead to several types of cancer. The agency says HPV vaccination has provided long lasting protection and has been associated with substantial reductions in infections involving HPV types that cause cancer and genital warts.
Another issue raised by the senators concerns the Vaccine Injury Compensation Program, a federal system designed to provide compensation in rare cases where covered vaccines cause qualifying injuries. The program operates as an alternative to traditional product liability litigation, with claims handled through the U.S. Court of Federal Claims. The senators want to know whether Kennedy’s department intends to change which injuries qualify for compensation, particularly given the previous involvement of Wisner Baum in cases seeking awards through the program.
What Happens Next in the Gardasil Dispute?
The controversy now places Kennedy at the center of questions involving financial disclosure, government ethics, vaccine policy and the administration of compensation programs. The immediate focus will be on the answers he provides to lawmakers and whether additional safeguards are introduced around decisions involving Gardasil.
The dispute does not establish that Kennedy or his family will financially benefit from the settlement, particularly given Wisner Baum’s statement denying that they will receive fees. Instead, the lawmakers are seeking greater clarity about potential financial connections and whether appropriate safeguards are in place. Whatever the outcome, the case highlights the importance of transparency when senior government officials have previous professional or financial connections to industries and legal cases that fall within their current responsibilities.
